nach oben

Die Onkologie

Erschienen in:

27.10.2017 | Hepatozelluläres Karzinom | Correction

Correction: Radioembolisation mit Yttrium-90-Mikrosphären

verfasst von: Univ.-Prof. Dr. med. U. Teichgräber, Univ.-Prof. Dr. med. B. Gebauer

Erschienen in: Die Onkologie | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Die selektive interne Radiotherapie ist eine innovative endovaskuläre minimalinvasive Therapie zur Behandlung von primären Leberneoplasien und Lebermetastasen.

Ziel

Es erfolgt eine Beschreibung der Technik und Anwendungsgebiete.

Ergebnisse

Die selektive interne Radiotherapie (SIRT) stellt inzwischen eine wichtige Säule in der Erst- und Zweitlinientherapie beim Cholangio- und hepatozellulären Karzinom dar. Bei Lebermetastasen kommt die Radioembolisation (⁹⁰Y-RE) meist zum Einsatz, wenn die Metastasierung unter Chemotherapie progredient ist und sich auf die Leber beschränkt („liver only“) oder dominant („liver dominant“) ist. Diese Therapieindikation wird vereinzelt auch als Salvage-Situation oder chemorefraktäre Situation bezeichnet.

Schlussfolgerung

Die Evidenzlage für die SIRT wird durch neuere Studien deutlich verbessert. Inzwischen findet die SIRT als alternatives Therapiekonzept für die Behandlung von Leberneoplasien Einzug in die onkologischen Leitlinien.

(Nccn) NCCN (2016) National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Hepatobiliary guidelines. V.1.2016

Abbott AM, Kim R, Hoffe SE et al (2015) Outcomes of therasphere radioembolization for colorectal metastases. Clin Colorectal Cancer 14:146–153CrossRefPubMed

Abdelfattah MR, Al-Sebayel M, Broering D et al (2015) Radioembolization using yttrium-90 microspheres as bridging and downstaging treatment for unresectable hepatocellular carcinoma before liver transplantation: initial single-center experience. Transplant Proc 47:408–411CrossRefPubMed

Arslan N, Emi M, Alagoz E et al (2011) Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for hepatic neuroendocrine metastases: initial experience at a single center. Vojnosanitetski pregled. Mil Med Pharm Rev 68:341–348

Barbier CE, Garske-Roman U, Sandstrom M et al (2016) Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging 43:1425–1431CrossRefPubMed

Bauschke A, Altendorf-Hofmann A, Freesmeyer M et al (2016) Selektive interne Radioembolisation beim nichtresektablen hepatozellulären Karzinom. Chirurg 87:956–963CrossRefPubMed

Bester L, Meteling B, Pocock N et al (2012) Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol 23:96–105CrossRefPubMed

Braat MN, Van Erpecum KJ, Zonnenberg BA et al (2017) Radioembolization-induced liver disease: a systematic review. Eur J Gastroenterol Hepatol 29:144–152CrossRefPubMed

Camacho JC, Kokabi N, Xing M et al (2014) Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. J Vasc Interv Radiol 25:256–265CrossRefPubMed

10.

Cao CQ, Yan TD, Bester L et al (2010) Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 97:537–543CrossRefPubMed

11.

Chamberlain RS, Canes D, Brown KT et al (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190:432–445CrossRefPubMed

12.

Cholapranee A, Van Houten D, Deitrick G et al (2015) Risk of liver abscess formation in patients with prior biliary intervention following yttrium-90 radioembolization. Cardiovasc Intervent Radiol 38:397–400CrossRefPubMed

13.

Chow PKH, Gandhi M (2017) Phase III multi-centre open-label randomized controlled trail of selective internal radiation therapy (SIRT) versus sorafenib in locally advanced hepatocellular carcinoma: The SIRveNIB study. J Clin Oncol 35(Suppl):Abs.4002

14.

Cosimelli M, Golfieri R, Cagol PP et al (2010) Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 103:324–331CrossRefPubMedPubMedCentral

15.

Dutton SJ, Kenealy N, Love SB et al (2014) FOXFIRE protocol: an open-label, randomised, phase III trial of 5‑fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. BMC Cancer 14:497CrossRefPubMedPubMedCentral

16.

Fan KY, Wild AT, Halappa VG et al (2016) Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization. Contemp Clin Trials 50:143–149CrossRefPubMed

17.

Geisel D, Powerski MJ, Schnapauff D et al (2014) No infectious hepatic complications following radioembolization with 90Y microspheres in patients with biliodigestive anastomosis. Anticancer Res 34:4315–4321PubMed

18.

Gil-Alzugaray B, Chopitea A, Inarrairaegui M et al (2013) Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 57:1078–1087CrossRefPubMed

19.

Golfieri R, Mosconi C, Giampalma E et al (2015) Selective transarterial radioembolisation of unresectable liver-dominant colorectal cancer refractory to chemotherapy. Radiol Med 120:767–776CrossRefPubMed

20.

Gray B, Van Hazel G, Hope M et al (2001) Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12:1711–1720CrossRefPubMed

21.

Hickey R, Lewandowski RJ, Prudhomme T et al (2016) 90Y radioembolization of colorectal hepatic metastases using glass microspheres: safety and survival outcomes from a 531-patient multicenter study. J Nucl Med 57:665–671CrossRefPubMed

22.

Hoffmann RT, Paprottka PM, Schon A et al (2012) Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol 35:105–116CrossRefPubMed

23.

Jelic S, Group EGW (2009) Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):41–45PubMed

24.

Jia Z, Paz-Fumagalli R, Frey G et al (2017) Single-institution Experience of Radioembolization with Yttrium-90 Microspheres for Unresectable Metastatic Neuroendocrine Liver Tumors. J Gastroenterol Hepatol. 2017 Jan 29. [Epub ahead of print]

25.

Kalinowski M, Dressler M, Konig A et al (2009) Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion 79:137–142CrossRefPubMed

26.

Kennedy AS, Ball D, Cohen SJ et al (2015) Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres. J Gastrointest Oncol 6:134–142PubMedPubMedCentral

27.

Kennedy AS, Ball DS, Cohen SJ et al (2016) Safety and efficacy of radioembolization in elderly (>/= 70 years) and younger patients with unresectable liver-dominant colorectal cancer. Clin Colorectal Cancer 15:141–151.e6CrossRefPubMed

28.

Kennedy AS, Dezarn WA, Mcneillie P et al (2008) Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31:271–279CrossRefPubMed

29.

King J, Quinn R, Glenn DM et al (2008) Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113:921–929CrossRefPubMed

30.

Kosmider S, Tan TT, Yip D et al (2011) Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer. J Vasc Interv Radiol 22(6):780–786CrossRefPubMed

31.

Lacin S, Oz I, Ozkan E et al (2011) Intra-arterial treatment with 90yttrium microspheres in treatment-refractory and unresectable liver metastases of neuroendocrine tumors and the use of 111in-octreotide scintigraphy in the evaluation of treatment response. Cancer Biother Radiopharm 26:631–637CrossRefPubMed

32.

Lau WY, Ho S, Leung TW et al (1998) Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 40:583–592CrossRefPubMed

33.

Lewandowski RJ, Memon K, Mulcahy MF et al (2014) Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy. Eur J Nucl Med Mol Imaging 41:1861–1869CrossRefPubMed

34.

Louie JD, Kothary N, Kuo WT et al (2009) Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolization. J Vasc Interv Radiol 20:606–613CrossRefPubMed

35.

Mahnken AH, Spreafico C, Maleux G et al (2013) Standards of practice in transarterial radioembolization. Cardiovasc Intervent Radiol 36:613–622CrossRefPubMed

36.

Maleux G, Deroose C, Laenen A et al (2016) Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival. Acta Oncol 55:486–495CrossRefPubMed

37.

Mayo SC, De Jong MC, Bloomston M et al (2011) Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol 18:3657–3665CrossRefPubMed

38.

Memon K, Lewandowski RJ, Mulcahy MF et al (2011) Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys 83(3):887–894CrossRefPubMedPubMedCentral

39.

Murthy R, Kamat P, Nunez R et al (2008) Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol 19:145–151CrossRefPubMed

40.

Murthy R, Xiong H, Nunez R et al (2005) Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol 16:937–945CrossRefPubMed

41.

Neumann UP, Neuhaus P, Seehofer D (2010) Chirurgische Therapie von Lebermetastasen beim kolorektalen Karzinom. Dtsch Arztebl Int 107:335–342PubMedPubMedCentral

42.

Osborne DA, Zervos EE, Strosberg J et al (2006) Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 13:572–581CrossRefPubMed

43.

Pape U‑F, Böhmig M, Tiling N et al (2000) Diagnostik und Therapie gastroenteropankreatischer neuroendokriner Tumore aus internistischer Sicht. Onkologe 6:624–633CrossRef

44.

Paprottka PM, Hoffmann RT, Haug A et al (2011) Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol 35(2):334–342CrossRefPubMed

45.

Peker A, Cicek O, Soydal C et al (2015) Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases. Diagn Interv Radiol 21:54–59CrossRefPubMed

46.

Rajekar H, Bogammana K, Stubbs RS (2011) Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment. Int J Hepatol 2011:404916CrossRefPubMedPubMedCentral

47.

Rhee TK, Lewandowski RJ, Liu DM et al (2008) 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 247:1029–1035CrossRefPubMed

48.

Ricke J, Bulla K, Kolligs F et al (2015) Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. Liver Int 35:620–626CrossRefPubMed

49.

Salem R, Gordon AC, Mouli S et al (2016) Y90 Radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 151:1155–1163.e2CrossRefPubMed

50.

Sangro B, Carpanese L, Cianni R et al (2011) Survival after Yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across barcelona clinic liver cancer stages: a European evaluation. Hepatology 54(3):868–878CrossRefPubMed

51.

Sangro B, Gil-Alzugaray B, Rodriguez J et al (2008) Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 112:1538–1546CrossRefPubMed

52.

Vilgrain V, Abdel-Rehim M, Sibert A, Ronot M, Lebtahi R, Castéra L, Chatellier G; SARAH Trial Group (2014) Radioembolisation with yttrium – 90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. Trials Dec. 3;15:474. ClinicalTrials.gov Identifier: NCT02807181

53.

Sato KT, Lewandowski RJ, Mulcahy MF et al (2008) Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres – safety, efficacy, and survival. Radiology 247:507–515CrossRefPubMed

54.

Saxena A, Bester L, Chua TC et al (2010) Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 17:484–491CrossRefPubMed

55.

Saxena A, Bester L, Shan L et al (2014) A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. J Cancer Res Clin Oncol 140:537–547CrossRefPubMed

56.

Saxena A, Chua TC, Bester L et al (2010) Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg 251:910–916CrossRefPubMed

57.

Saxena A, Meteling B, Kapoor J et al (2015) Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients. Ann Surg Oncol 22:794–802CrossRefPubMed

58.

Schwarz RE, Abou-Alfa GK, Geschwind JF et al (2010) Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford) 12:313–320CrossRef

59.

Shaheen M, Hassanain M, Aljiffry M et al (2012) Predictors of response to radio-embolization (TheraSphere(R)) treatment of neuroendocrine liver metastasis. HPB (Oxford) 14:60–66CrossRef

60.

Sharma RA (2017) Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastasis from colorectal cancer. J Clin Oncol 35

61.

Sharma RA, Van Hazel GA, Morgan B et al (2007) Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 25:1099–1106CrossRefPubMed

62.

Sircca SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma (SIRCCA). In: ClinicalTrials.gov Studienregister, Identifier: NCT02807181

63.

Ricke J1, Bulla K, Kolligs F, Peck-Radosavljevic M, Reimer P, Sangro B, Schott E, Schütte K, Verslype C, Walecki J, Malfertheiner P; SORAMIC study group (2015) Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. Liver Int. 35(2):620–626

64.

Stop-Hcc Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer (STOP-HCC). In: ClinicalTrials.gov studienregister, Identifier: NCT01556490

65.

Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281CrossRefPubMed

66.

Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386–1422CrossRefPubMed

67.

Van Hazel GA, Heinemann V, Sharma NK et al (2016) SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 34:1723–1731CrossRefPubMed

68.

Vilgrain V, Bouattour M, Sibert A et al (2017) SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma (Abstract GS-012). J Hepatol 66:2

69.

Whitney R, Valek V, Fages JF et al (2011) Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost. Oncologist 16:594–601CrossRefPubMedPubMedCentral

70.

Yang TX, Chua TC, Morris DL (2012) Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases – a systematic review. Surg Oncol 21:299–308CrossRefPubMed

Titel: Correction: Radioembolisation mit Yttrium-90-Mikrosphären
verfasst von: Univ.-Prof. Dr. med. U. Teichgräber
Univ.-Prof. Dr. med. B. Gebauer
Publikationsdatum: 27.10.2017
Verlag: Springer Medizin
Schlagwörter: Hepatozelluläres Karzinom
Zytostatische Therapie
Hepatozelluläres Karzinom
Erschienen in: Die Onkologie / Ausgabe 11/2017
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI: https://doi.org/10.1007/s00761-017-0304-9

Passend zum Thema

Synergien nutzen gegen Tumore

Magenkarzinom

Lungen- und Magentumore können dank Immuntherapien deutlich besser behandelt werden. Dennoch kommt es trotzdem weiterhin häufig zum Krankheitsprogress. Welche Therapieoptionen sich in der Zweitlinie am besten eignen, haben wir für Sie zusammengefasst.

Darmkrebsreihenuntersuchungen zeigen EU-weit Erfolge

Kolonkarzinom

In Europa haben viele Länder dem Darmkrebs mit Hilfe von Früherkennungsprogrammen den Kampf angesagt. Es gibt einen deutlichen Zusammenhang zwischen Inzidenz und Mortalität von Darmkrebs und der Zeitspanne seit Einführung von Reihenuntersuchungen.

GI-Tumore und die Rolle von Angiogenesehemmern

Content Hub

Entdecken Sie mit praxisrelevanten Patientenfällen, kompakten Studieninhalten, informativen Experteninterviews und weiteren spannenden Inhalten, wie Sie den vielseitigen Herausforderungen bei GI-Tumoren begegnen können. Hier erfahren Sie mehr! _{PP-RB-DE-2009}

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Hintergrund

Ziel

Ergebnisse

Schlussfolgerung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2017

Versorgungsforschung in der Psychoonkologie

Versorgungsrealität der molekularen Diagnostik maligner Erkrankungen

Versorgungsforschung

Versorgungsforschung in der Onkologie

Versorgungsforschung in der Radioonkologie am Beispiel der Körperstereotaxie

Versorgungsforschung in onkologischen Schwerpunktpraxen in Deutschland

Passend zum Thema

Synergien nutzen gegen Tumore

Darmkrebsreihenuntersuchungen zeigen EU-weit Erfolge

GI-Tumore und die Rolle von Angiogenesehemmern